Dr. Saad on Next Steps for Radium-223 in mCRPC

Fred Saad, MD
Published: Monday, Oct 26, 2015



Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Next steps with this therapy include examining this agent in combination with other drugs, such as abiraterone and enzalutamide, Saad explains. A phase II study also examined the safety of radium-223 when added to chemotherapy, which showed promise.

There are no safety concerns with administering radium-223 before or after chemotherapy, he adds.
 


Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Next steps with this therapy include examining this agent in combination with other drugs, such as abiraterone and enzalutamide, Saad explains. A phase II study also examined the safety of radium-223 when added to chemotherapy, which showed promise.

There are no safety concerns with administering radium-223 before or after chemotherapy, he adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x